‘Questionable’ patent on key HIV drug is challenged in Brazil
Legal challenge essential to prevent further barriers to optimal HIV treatment in Brazil. ABIA, our campaign partner in Brazil, is...
São Paulo protest exposes how Gilead’s actions block access to medicines around the world
In São Paulo, on 31 October 2017, activists from around the world held a protest at the headquarters of...
Intellectual Property Group opposes a resolution which would restrict access to medicines in Brazil
Our partner in Brazil highlights the facts in a debate full of confusion Last month, the Working Group on Intellectual...
Brazil: Open letter insists that pharmaceuticals’ interests must NOT be prioritized over public health
The Working Group on Intellectual Property responds to what it sees as ‘an attack on the rights of the Brazilian...
#TreatPeopleRight – Highlights from the ITPC Annual Review
Campaign activity contributing to combined savings of US$700 million for health budgets is among ITPC’s 2016 highlights The mission of...
Brazilian Activists: Third-party in a legal case, to prevent weakening of patent system
On April 7, the Working Group on Intellectual Property of the Brazilian Network for the Integration of Peoples (GTPI/Rebrip), filed...
Brazil: People waiting for Hep C cure caught between a life-changing decision – and an attempt to block it
Anvisa’s decision would allow the purchase of generics, and increase access to quality Hep C treatment – but a simultaneous...
Brazilian National Institute of Industrial Property Rejects Truvada® Patent Application
On 24 January 2017, Brazil’s National Institute of Industrial Property (INPI) made public a decision to reject the patent application...
Pressure leads to incorporation of new antiretroviral
The incorporation of a new antiretroviral in Brazil’s national treatment guidelines, and the scale up of a second-line treatment are...
Seminar: Policies around Access to Medicines & Human Rights
Watch the presentations of the "Sustainability, Health Systems and Human Rights" at the Seminar on Policies of Access to Medicines and Human Rights.